-+ 0.00%
-+ 0.00%
-+ 0.00%

Press Release: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting

Dow Jones·11/11/2024 12:00:00

Please log in to view news